What a molecular NGS second opinion covers.
A molecular second opinion re-evaluates your existing NGS report and turns it into a physician-reviewed, signed, tumor-specific and prioritized treatment roadmap. It tells you not just what the report found, but what to do, in what order, and what to avoid.
What is a molecular second opinion?
A molecular second opinion is an independent, physician-led re-interpretation of a tumor's NGS data. Rather than repeating the test, it evaluates the existing report against current guidelines and literature, producing a patient-specific, prioritized and sequenced treatment plan the treating oncologist can act on.
The bottleneck in precision oncology is no longer running the test — it is reading it correctly. A modern panel can return dozens of variants of unknown significance and a short, automated summary that never meets the patient. A second opinion closes the gap between raw genomic data and an actionable, reasoned decision.
What the advisory report covers.
Variant tier classification
Every variant is graded Tier I–IV (AMP / ASCO / CAP) and re-graded against your tumor type and line of therapy.
Immunotherapy eligibility
A transparent score derived from TMB, MSI, PD-L1 and driver-mutation context, with the "IO indicated / not indicated" rationale stated explicitly.
Treatment sequencing
A preferred 1L with alternatives, a 2L matched to expected resistance, and 3L+ options — each presented with its evidence level.
A predictive resistance plan
What to test for at progression, which resistance mechanisms to expect, and which next-generation agents or trials respond to each.
Multi-platform integration
DNA, RNA and IHC are assessed together; any discordance (e.g. RNA-positive but DNA-negative) is resolved or flagged for the correct confirmatory test.
Clinical-trial matching
Molecular and HLA eligibility are checked against current trial databases, with NCT id, phase and geography.
Physician commentary
A personal, physician-to-physician letter from Prof. Dr. İbrahim Yıldız, in your chosen report language.
Evidence & sources
Every recommendation is traced to NCCN, ESMO, OncoKB and current peer-reviewed literature, timestamped to the date the report was written.
What it does and does not do.
NGS Advisory provides decision support for the treating physician. This is not a diagnosis, not a medical device, and does not replace clinical judgment.
Tier I–IV, re-graded against your tumor.
Using the AMP / ASCO / CAP framework, every variant is graded for clinical actionability, then re-graded against the specific tumor type and line of therapy. A biomarker that is Tier I in one cancer can be Tier II — or entirely irrelevant — in another, so the tier is always read in context.
Before you ask.
I already have an NGS report. Why get a second opinion on it?
An NGS report lists findings; it does not build a treatment strategy. A molecular second opinion takes the same data and turns it into a prioritized, sequenced plan for your tumor type and line of therapy — including what not to do.
Do I need a new test?
No. The advisory works from your existing report (Tempus, FoundationOne, Guardant, Caris, or any panel). Where more than one platform exists (DNA, RNA, IHC) they are integrated; new testing is recommended only when a specific finding needs confirmation.
Does it replace my oncologist?
No. This is decision support, not a diagnosis. Every recommendation is written for your treating oncologist, who retains full authority over the treatment decision.
How long does it take, and in what language?
The structured advisory report, with priority and STAT options, is typically delivered within 72 hours in English (the international standard in molecular genomics). The physician commentary can be delivered in your preferred language.
Before the plan is signed, an experienced second look.
Submit your existing NGS report securely. Most advisory reports are delivered within 72 hours.